EUCTR2006-001488-51-DE进行中（未招募）1 期
A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY, TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF THE MGLUR5 NEGATIVE ALLOSTERIC MODULATOR ADX10059 IN THE ACUTE TREATMENT OF MIGRAINE
Addex Pharmaceuticals S.A.0 个研究点目标入组 150 人开始时间: 2006年6月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Female and male patients aged 18 to 65 years.
- •2.Diagnosis of migraine with or without aura according to IHS criteria 1.1 and 1.2.1
- •3.Onset of migraine history prior to age 50 years
- •4.Patients who have between 2 and 8 moderate or severe migraine headaches per month.
- •5.Ability to communicate well with the study staff and to comply with the requirements of the entire study.
- •6.Patients who have provided written informed consent to participate in this study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Administration of any investigational drug up to 30 days before study entry or parallel participation in another study
- •2.Patients with more than 15 headache days per month.
- •3.Patients with known clinically significant allergy or known hypersensitivity to ADX10059 or lactose.
- •4.Patients who have abnormal laboratory parameters at screening, in particular, liver or renal functions tests greater than twice the upper limit of normal or any other clinically significant biochemical or hematological abnormality as determined by the investigator.
- •5.Patients with a history of a significant medical or psychiatric condition that may affect the safety of the patient or preclude adequate participation in the study.
- •6.Patients who are pregnant or breast-feeding. Female patients who are of child bearing potential must be using adequate contraceptive methods (e.g. oral contraceptives, intra uterine device (IUD), double barrier method (e.g. spermicide plus condom or diaphragm plus spermicide) and intra muscular hormonal contraceptive).
- •7.Patients using migraine prophylaxis must have been on stable doses of the prophylactic agent for least 12 weeks prior to study entry.
- •8. Patients taking sodium valproate or valproic acid or patients who have taken either of these within the last 30 days.
研究者
相似试验
已完成
3 期
A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN AS ADJUNCTIVE THERAPY IN CHILDREN 4 -16 YEARS OF AGE WITH PARTIAL ONSET SEIZURESEpilepsy with partial onset seizures10039911NL-OMON39878Pfizer3
进行中（未招募）
1 期
A safety and efficacy study of pregabalin in children 4-16 years of age for partial onset seizuresPartial onset seizuresMedDRA version: 14.1Level: LLTClassification code 10034089Term: Partial seizures NOSSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-020852-79-GRPfizer Inc.235 East 42nd Street, New York, NY 10017225
进行中（未招募）
1 期
A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF PREGABALIN AS ADJUNCTIVE THERAPY IN CHILDREN 1 MONTH THROUGH <4 YEARS OF AGE WITH PARTIAL ONSET SEIZURES - Pregabalin, Phase 3 Study in children < 4 years of age with partial onset seizuresPartial onset seizuresMedDRA version: 18.0Level: LLTClassification code 10034089Term: Partial seizures NOSSystem Organ Class: 100000004852EUCTR2013-003420-37-PTPfizer Inc. 235 East 42nd Street, New York, NY 10017175
进行中（未招募）
1 期
A safety and efficacy study of pregabalin in children 4-16 years of age for partial onset seizuresEUCTR2010-020852-79-EEPfizer Inc.235 East 42nd Street, New York, NY 10017295
进行中（未招募）
1 期
A safety and efficacy study of pregabalin in children 4-16 years of age for partial onset seizuresPartial onset seizuresMedDRA version: 14.0Level: LLTClassification code 10034089Term: Partial seizures NOSSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-020852-79-FRPfizer Inc.235 East 42nd Street, New York, NY 10017153